Filing Details
- Accession Number:
- 0001209191-23-048845
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-08 19:00:27
- Reporting Period:
- 2023-09-07
- Accepted Time:
- 2023-09-08 19:00:27
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1679363 | Morphic Holding Inc. | MORF | Pharmaceutical Preparations (2834) | 473878772 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1773184 | Marc Schegerin | C/O Morphic Holding, Inc. 35 Gatehouse Drive, A2 Waltham MA 02451 | Cfo And Coo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-09-07 | 20,000 | $15.00 | 44,136 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-09-07 | 6,691 | $53.20 | 37,445 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-09-07 | 13,309 | $54.92 | 24,136 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy Common Stock) | Disposition | 2023-09-07 | 20,000 | $0.00 | 20,000 | $15.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 57,268 | 2030-04-05 | No | 4 | M | Direct |
Footnotes
- Includes 396 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 28, 2022.
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person dated June 28, 2022.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.19 to $55.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The option vested as to 25% of the total shares on April 6, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on April 6, 2024, subject to the reporting person's provision of service to the Issuer on each vesting date.
Billionaire Hedge Funds
